Fund Evaluator:
iShares US Medical Devices ETF (IHI)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$243.360
NAV (as of Oct 07)
$0.00
Minimum Initial
0.37% B
Expense Ratio
$3,473 Mil
Assets
Open
Status
na
12b-1 Fee
0.44%
TTM Yield
0.00%
Max Load
12%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 67.1% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 66.9% | Fidelity Advisor Biotechnology I (FBTIX) |
| 58.0% | Fidelity Select Biotechnology (FBIOX) |
| 54.2% | Rydex Biotechnology Inv (RYOIX) |
| 49.7% | Eventide Healthcare & Life Sciences N (ETNHX) |
Data as of 8/31/2026
4.7% D
1-Mo Return
12.4% D
3-Mo Return
-11.4% F
YTD Return
-11.2% F
1-Yr Return
2.0% F
3-Yr Return
-3.0% F
5-Yr Return
0.87 C
Category Risk Index
1.46
Total Risk Index
Fund Details
Fund Family
iShares
Inception Date
5/1/2006
Share Class Type
Equity Investment Style
Mid-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
S&P US TMI TR USD: 100%
Additional Fund Details
iShares US Medical Devices ETF Overview
IHI Trailing NAV Total Returns Data as of 8/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| IHI Return (NAV) | 4.7% | 12.4% | -11.2% | 2.0% | -3.0% | 9.1% |
| IHI Grade | D | D | F | F | F | D |
| +/- Category | -0.3% | -1.0% | -44.1% | -11.1% | -8.3% | -1.1% |
| Health Avg | 5.0% | 13.4% | 32.9% | 13.1% | 5.2% | 10.2% |
| IHI Tax Cost Ratio | na | na | 0.1% | 0.1% | 0.1% | 0.1% |
IHI Annual NAV Total ReturnsData as of 8/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| IHI Return (NAV) | -11.4% | 6.9% | 8.6% | 3.2% | -19.7% | 21.0% | 24.2% | 32.7% | 15.5% | 30.9% | 9.2% |
| IHI Grade | F | F | A | C | D | A | C | A | A | B | A |
| +/- Category | -23.8% | -13.7% | 6.1% | -2.3% | -10.3% | 12.3% | -0.3% | 4.3% | 15.1% | 7.5% | 20.1% |
| Health Avg | 12.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 17.8% |
| Total Risk Index: | 1.46 - Above Average |
| Category Risk Index: | 0.87 - Average |
| Category Risk Grade: | C (46% Rank) |
| Beta: | 0.79 |
| R-Squared: | 30% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.4% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | Annually |
| Total Assets: | $3473 Mil |
| Fund Total Assets: | $3,474 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 12% |
Management Team
| Number of Managers: 4 | |||
| Longest Tenure: 14.0 years | |||
| Average Tenure: 4.6 years | |||
| Managers (Year): Hsui Jennifer (2012), Sietsema Peter (2025), Waldron Matt (2025), White Steven (2025) | |||
Portfolio Composition (as of 8/31/26)
| # of Holdings: | 51 |
| % in Top 10 Holdings: | 74.6% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 0.0% |
Portfolio Allocation |
|
| Domestic Stock: | 99.9% |
| Foreign Stock: | 0.0% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Fund Family: | iShares |
| Phone Number: | 800-474-2737 |
| Website: | au.ishares.com |
| Status: | Open |
| Inception Date: | May 1, 2006 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.37% ( Rating : Below Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | iShares US Medical Devices ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.